Request that the FDA take the following three actions described below: 1) To determine that the preclusion date referenced in the statute (i.e., the date on which the race to market between a drug and a supplement is adjudicated) is the date the existence of substantial clinical trials are made public, not the non-public date on which an investigational new drug (IND) application goes into